论文部分内容阅读
目的探讨Choi免疫学分型在新疆维吾尔族弥漫大B细胞淋巴瘤(DLBCL)中的作用及预后意义。方法采用EnVision二步法检测78例新疆维吾尔族DLBCL肿瘤组织中的GCET1、FOXP1、CD10、bcl-6、MUM1的表达,并对其进行Choi免疫学分型,采用Kaplan-Meier法进行生存分析,Cox比例风险模型分析影响预后的因素。结果 CD10、bcl-6、MUM1、GCET1、FOXP1的阳性率分别为19.2%(15/78)、24.4%(19/78)、62.8%(49/78)、30.8%(24/78)、53.8%(42/78)。生发中心样B细胞(GCB)型DLBCL与非生发中心样B细胞(non-GCB)型DLBCL所占比例分别为29.5%(23/78)、70.5%(55/78)。全组患者中位生存时间为28个月(95%CI:16.1~39.9个月),3年总生存率(OS)为46%。GCB组与non-GCB组的3年OS分别为58%与39%,差异有统计学意义(P<0.01),多因素分析显示,国际预后指数(IPI)及免疫学分型是新疆吾尔族DLBCL患者的独立预后因素。结论新疆维吾尔族DLBCL以non-GCB型为主,Choi免疫学分型法有助于判断新疆维吾尔族DLBCL预后。
Objective To investigate the role and prognostic significance of Choi immunological typing in Uygur diffuse large B cell lymphoma (DLBCL) in Xinjiang Uygur Autonomous Region. Methods The expression of GCET1, FOXP1, CD10, bcl-6 and MUM1 in 78 DLBCL tumor tissues from Xinjiang Uigur patients was detected by EnVision two-step method. Choi immunological typing was performed and the survival analysis was performed by Kaplan-Meier method. Proportional risk model analysis of prognostic factors. Results The positive rates of CD10, bcl-6, MUM1, GCET1 and FOXP1 were 19.2% (15/78), 24.4% (19/78), 62.8% (49/78), 30.8% % (42/78). The proportions of germinal center-like B cells (DLBCL) and non-GCB DLBCL were 29.5% (23/78) and 70.5% (55/78), respectively. The median overall survival was 28 months (95% CI: 16.1-39.9 months) and 3-year overall survival (OS) was 46%. The 3-year OS of GCB group and non-GCB group were 58% and 39%, respectively, with significant difference (P <0.01). Multivariate analysis showed that the international prognostic index (IPI) Independent prognostic factors in DLBCL patients. Conclusion DLBCL in Xinjiang Uygur mainly non-GCB type, Choi immunological typing helps to determine the prognosis of Uigur DLBCL in Xinjiang.